| Literature DB >> 32764718 |
Dannuey Machado Cardoso1,2, Ricardo Gass3,4, Graciele Sbruzzi4,5, Danilo Cortozi Berton4,6, Marli Maria Knorst4,6.
Abstract
Expiratory positive airway pressure (EPAP) is widely applicable, either as a strategy for pulmonary reexpansion, elimination of pulmonary secretion or to reduce hyperinflation. However, there is no consensus in the literature about the real benefits of EPAP in reducing dynamic hyperinflation (DH) and increasing exercise tolerance in subjects with chronic obstructive pulmonary disease (COPD). To systematically review the effects of EPAP application during the submaximal stress test on DH and exercise capacity in patients with COPD. This meta-analysis was performed from a systematic search in the PubMed, EMBASE, PeDRO, and Cochrane databases, as well as a manual search. Studies that evaluated the effect of positive expiratory pressure on DH, exercise capacity, sensation of dyspnea, respiratory rate, peripheral oxygen saturation, sense of effort in lower limbs, and heart rate were included. GRADE was used to determine the quality of evidence for each outcome. Of the 2,227 localized studies, seven studies were included. The results show that EPAP did not change DH and reduced exercise tolerance in the constant load test. EPAP caused a reduction in respiratory rate after exercise (- 2.33 bpm; 95% CI: - 4.56 to - 0.10) (very low evidence) when using a pressure level of 5 cmH2O. The other outcomes analyzed were not significantly altered by the use of EPAP. Our study demonstrates that the use of EPAP does not prevent the onset of DH and may reduce lower limb exercise capacity in patients with COPD. However, larger and higher-quality studies are needed to clarify the potential benefit of EPAP in this population.Entities:
Mesh:
Year: 2020 PMID: 32764718 PMCID: PMC7413366 DOI: 10.1038/s41598-020-70250-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Analysis of pressure subgroups.
| Outcome | Subgroup analyses | Result |
|---|---|---|
| Inspiratory capacity | 5–7.5 cmH2O24(a),27 | 0.02 L (95% CI − 0.30 to 0.34, I2 = 0%) |
| 7.5–10 cmH2O17,18,24(b),26,27 | − 0.05 L (95% CI − 0.24 to 0.15, I2 = 14%) | |
| Exercise capacity (Tlim) | 5–7.5 cmH2O24(a),27 | − 224.8 s (95% CI − 417.6 to − 32.0, I2 = 0%) |
| 7.5–10 cmH2O24(b),27 | − 230.65 s (95% CI − 423.6 to − 37.6, I2 = 0%) | |
| Peripheral oxygen saturation | 5–7.5 cmH2O24(a),25,27 | 0.57% (95% CI − 0.44 to 1.59, I2 = 16%) |
| 7.5–10 cmH2O17,24(b),26,27 | 0.58% (95% CI − 0.93 to 2.09, I2 = 3%) |
Tlim total exercise time.
(a)Considering the pressure level of 5 cmH2O; (b)Considering the pressure level of 10 cmH2O.
Figure 1Flow diagram of the studies included. EPAP: Expiratory positive airways pressure.
Characteristics of included studies using positive expiratory pressure through a device.
| Author, year | Intervention device | Participants | Comparator | N IG/CG | Age (sd) IG/CG | Gender masc. IG/CG | Protocol | Outcomes |
|---|---|---|---|---|---|---|---|---|
| van der Schans et al.[ | EPAP face mask with unidirectional valve (Vital Signs, Totowa, USA) | Moderate to very severe COPD | Control situation—exercise without EPAP | 8 | 64 (4) | 8 | Incremental CEPT in a cycle ergometer with an increment of 10 w per minute and 60 revolutions per minute in normal breathing and with 5 cmH2O EPAP | CEPT with EPAP caused a reduction in RR and a greater sensation of dyspnea and exertion |
| Monteiro et al.[ | EPAP face mask with spring linear pressure resistor (Vital Signs USA) with unidirectional expiratory valve | Moderate to very severe COPD | Control situation—constant CEPT without EPAP | 17 | 62.6 (9.9) | 10 | Constant CEPT on treadmill performed every other day and not randomized without EPAP and with EPAP ranging from 5 to 10 cmH2O (average 8 cmH2O) | The use of EPAP caused a lower decrease in IC |
| Nicolini et al.[ | PEP value valve (Respironics, USA) connected to a pipe and nozzle | Moderate to severe COPD | Control group—6MWT without PEP | 50/50 | 71.9 (4.0)/72.1 (4.1) | 26/32 | 6MWT in normal breathing and with 5 cmH2O PEP | Increased walking distance in the 6MWT using PEP |
| Wibmer et al.[ | EPAP face mask (Joyce, Weinmann Gerat für Medizin GmbH + Co. Germany) with resistor (PARI PEP System I, Pari GmbH, Germany) | Moderate to severe COPD | Control situation—6MWT without EPAP | 20 | 69.4 (6.4) | 13 | 6MWT with EPAP ranging from 10–20 cmH2O, depending on expiratory flow | Greater decrease in SpO2 and shorter walking distance in 6MWT with EPAP application |
| Goelzer et al.[ | Spring resistor EPAP face mask (Vital Signs, USA) and unidirectional inspiratory valve (PARI PEP System, Respiratory Equipment, Inc., USA) | Severe to very severe COPD | Control situation—intervention without EPAP | 16 | 64.5 (7.3) | 12 | Constant speed CEPT on treadmill at 70–80% of the maximum speed achieved in incremental CEPT, with the use of approximately 7.5 cmH2O EPAP | Less exercise time with EPAP |
| Russo et al.[ | Two-way EPAP face mask (PEEP Valve, Ambu, Denmark), with pre | Severe to very severe COPD | Control situation—6MWT with 1 cmH2O EPAP | 50 | 69.9 (7.3) | 35 | Application of 10 cmH2O EPAP during the 6MWT | There was no significant change in the variables analyzed with the use of EPAP |
| Gass et al | Non-inhalable T-shaped 2-way valve face mask (2,600 Medium, Hans Rudolph, KS) without diaphragms (0 cmH2O), with diaphragm (5 cmH2O) and EPAP-associated (10 cmH2O) | Moderate to very severe COPD | Control situation—constant CEPT without EPAP | 15 | 60.9 (12.3) | 8 | Constant CEPT in lower limb cycle ergometer performed on alternate days and in random order without the use of EPAP, with 5 cmH2O and 10 cmH2O EPAP | Reduced exercise capacity with 10 cmH2O EPAP |
IG intervention group, CG control group, EPAP expiratory positive airway pressure, PEP positive expiratory pressure, CEPT cardiopulmonary exercise test, COPD chronic obstructive pulmonary disease, 6MWT 6-min walk test, 1-RM one repetition maximum tests, f breathing frequency, IC Inspiratory capacity, S oxyhemoglobin saturation by pulse oximetry.
Risk of bias of included studies.
| Adequate sequence generation | Allocation concealment | Blinding of patients | Blinding of outcome assessors | Description of losses and exclusions | Intention-to-treat analysis | |
|---|---|---|---|---|---|---|
| van der Schans et al.[ | No | No | No | No | Yes | No |
| Monteiro et al.[ | No | No | No | No | Yes | No |
| Nicolini et al.[ | Yes | Yes | Yes | Yes | Yes | No |
| Wibmer et al.[ | Yes | No | No | No | Yes | No |
| Goelzer et al.[ | No | No | No | No | Yes | No |
| Russo et al.[ | No | No | No | No | Yes | No |
| Gass et al.[ | Yes | No | No | No | Yes | No |
Figure 2Comparison of inspiratory capacity without EPAP versus EPAP from 5 to 10 cmH2O. a5 cmH2O; b10cmH2O.
Quality of evidence using The GRADE approach.
| Certainty assessment | N | Absolute | Certainty | |||||
|---|---|---|---|---|---|---|---|---|
| N (trials) | Risk of Bias | Inconsistency | Indirectness | Imprecision | Intervention | Comparation | (95% CI) | |
| 5 | Very Seriousa | Not Serious | Not Serious | Seriousc | 118 | 118 | − 0.02 (95% CI − 0.19 to 0.16) | Very low |
| 3 | Very Seriousa | Not Serious | Not Serious | Seriousc | 85 | 85 | 0.04 (95% CI − 0.16 to 0.24) | Very low |
| 2 | Very Seriousa | Not Serious | Not Serious | Very Seriousc | 31 | 31 | − 214.8 (95% CI − 400.2 to − 29.4) | Very low |
| 3 | Very Seriousa | Not Serious | Not Serious | Very Seriousc | 120 | 120 | 1.7 (95% CI − 35.7 to 39.1) | Very low |
| 2 | Very Seriousa | Not Serious | Not Serious | Very Seriousc | 70 | 70 | − 21.3 (95% CI − 63.3 to 20.7) | Very low |
| 2 | Very Seriousa | Not Serious | Not Serious | Not Serious | 65 | 65 | − 2.3 (95% CI − 4.5 to − 0.1) | LOW |
| 2 | Very Seriousa | Not Serious | Not Serious | Very Seriousc | 65 | 65 | − 0.1 (95% CI − 2.7 to 2.4) | Very low |
| 2 | Very Seriousa | Not Serious | Not Serious | Very Seriousc | 65 | 65 | 0.5 (95% CI − 0.7 to 1.9) | Very low |
| 3 | Very Seriousa | Not Serious | Not Serious | Very Seriousc | 85 | 85 | 0.7 (95% CI − 0.9 to 2.4) | Very low |
| 5 | Very Seriousa | Not Serious | Not Serious | Very Seriousc | 166 | 166 | 0.5 (95% CI − 0.4 to 1.5) | Very low |
| 3 | Very Seriousa | Not Serious | Not Serious | Very Seriousc | 73 | 73 | − 0.2 (95% CI − 2.8 to 2.2) | Very low |
| 3 | Very Seriousa | Not Serious | Not Serious | Very Seriousc | 85 | 85 | 0.4 (95% CI − 0.4 to 1.3) | Very low |
| 2 | Very Seriousa | Not Serious | Not Serious | Very Seriousc | 65 | 65 | 0.1 (95% CI − 0.3 to 0.7) | Very low |
N (trials) number of articles with outcome assessment, IC Inspiratory capacity, Tlim total exercise time, 6MWT six-minute-walk-test, f breathing frequency, S oxyhemoglobin saturation by pulse oximetry.
aSome studies do not report whether there was allocation concealment, whether there was blinding of patients and outcome assessors and whether the analysis was performed by intention to treat; bHigh heterogeneity (over 50%); cLarge confidence interval (CI).
Figure 3Comparison between exercise capacity with EPAP application at different pressure levels. a5 cmH2O; b10cmH2O.
Figure 4Comparison of dyspnea sensation assessed by the Borg scale, with 5 and 10 cmH2O EPAP. a5 cmH2O; b10cmH2O.
Figure 5Comparison between respiratory rate with EPAP application at different pressure levels. a5 cmH2O; b10cmH2O.
Figure 6Comparison of oxyhemoglobin saturation by pulse oximetry with 5–10 cmH2O EPAP. a5 cmH2O; b10cmH2O.
Figure 7Comparison of leg discomfort assessed using the Borg scale, with 10 cmH2O EPAP. b10cmH2O.